Microcephaly
16
3
3
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.3%
1 terminated out of 16 trials
90.9%
+4.4% vs benchmark
0%
0 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (16)
MEHMO Natural History and Biomarkers
The FBRI VTC Neuromotor Research Clinic
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
Summary of Infants Weighing 500 Grams or Less
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
Guangzhou Surveillance and Clinical Study in Microcephaly (GSCSM)
Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay
Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
Microcephaly Genetic Deficiency in Neural Progenitors
Zika and Microcephaly: Case-control Study
Fetal and Maternal Head Circumference During Pregnancy in Israeli Population
Evaluation of Patients With Unresolved Chromosome Abnormalities